🇺🇸 FDA
Pipeline program

Isatuximab, bortezomib, lenalidomide, dexamethason

K9520

Approved small_molecule active

Quick answer

Isatuximab, bortezomib, lenalidomide, dexamethason for Multiple Myeloma is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Multiple Myeloma
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials